Epitan raises $8 million in private placement
Wednesday, 11 August, 2004
EpiTan (ASX: EPT) has raised AUD$7.98 million via a private placement of 10.5 million fully paid ordinary with two European investors.
The shares were issued at AUD$0.76, a 6.4 per cent discount to the three-month volume weighted average price of AUD$0.91.
8.5 million shares were placed with FM Fund Management, run out of Zurich by hedge fund manager Florian Homm. Its Absolute Return Europe Fund is now a substantial shareholder in EpiTan, holding 6.8 per cent of the company’s shares.
A further 2 million shares were placed with UK biotech investment fund Mercury Investments.
Epitan also issued 6.6 million unlisted options exercisable over three years at AUD$1.03, which would provide it with a further AUD$6.87 in cash. EpiTan’s executive chairman and CEO, Dr Wayne Millen said the placement bought Epitan’s cash reserves to approximately AUD$13 million.
At time of writing shares in Epitan were trading at $0.87.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...